Last Updated: 2/19
Share or print this information to talk to your doctor about this trial.
The purpose of this study is to evaluate the safety and tolerability of OMS721 in subjects with IgA Nephropathy (IgAN), Lupus Nephritis (LN), Membranous Nephropathy (MN), and C3 Glomerulopathy (C3G), including Dense Deposit Disease. The study will also evaluate Pharmacokinetics (PK), Pharmacodynamics (PD), anti-drug antibody response (ADA), and neutralizing antibodies (Nab).
Interventions
Phase
2
Status
Recruiting
Conditions
Ages
18 and older
Sexes
All
Omeros Investigational Site
Denver, CO 80230
Augusta, GA 30909
Evergreen Park, IL 60805
Voorhees, NJ 08043
Flushing, NY 11355
San Antonio, TX 78215
Milwaukee, WI 53226
Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contact information provided below.
Soyoung Han | 206-676-5000
shan@omeros.com
Omeros
www.omeros.com
View complete study information on ClinicalTrials.gov
Thank you for visiting WeC3GTM
You are now leaving the WeC3G.com website and being directed to a third-party website. Achillion Pharmaceuticals, Inc. is not responsible for the content of the site you are about to visit.
Would you like to continue?
To ensure you receive the best user experience, our site uses cookies to store information in your browser.
To find out more, view our Privacy Policy.
Continued use of this site indicates you have accepted this policy.